atoltivimab

atoltivimab (INMAZEB) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.

INMAZEB is a marketed brand name for atoltivimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

atoltivimab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.